在资源有限的环境中,新诊断的多发性骨髓瘤患者的治疗模式和结果
Chin Sum Cheong1, Tengku Ahmad Hidayat Tengku K Aziz2, Nur Adila Anuar3
1Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
Asian Pacific journal of cancer prevention : APJCP
|February 28, 2024
概括
在马来西亚,含博雷佐米布的疗法改善了新诊断多发性骨髓瘤 (NDMM) 患者的治疗结果. 实现非常好的部分反应 (VGPR) 和前期自身干细胞移植 (ASCT) 是改善生存的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 多发性骨髓瘤是马来西亚的一个显著的血液恶性瘤.
- 新型代理商可以改善结果,但在资源有限的环境中,它们会带来经济挑战.
- 这项研究检查了新诊断的多发性骨髓瘤 (NDMM) 在这样的环境中的现实世界治疗模式和结果.
研究的目的:
- 报告在资源有限的环境中NDMM患者的现实世界治疗模式和结果.
- 评估不同治疗方案的有效性及其与患者存活率的关联.
主要方法:
- 对136名在2008年至2022年期间被诊断为NDMM患者的回顾性研究.
- 对人口统计数据,治疗细节,无进展生存率 (PFS) 和总生存率 (OS) 的分析.
主要成果:
- 含有博尔特佐米布的疗法是最常见的诱导疗法.
- 几乎一半的患者实现了非常好的部分反应 (VGPR) 或完全缓解 (CR).
- 博尔特佐米布使用与更深,更快的反应相关 (p=0.001,p=0.017);中位数的生存期为60.0个月,中位数的PFS为25.0个月.
结论:
- 至少达到VGPR显著改善了NDMM患者的结果.
- 建议在资源有限的环境中将博特佐米布诱导疗法和前期自身干细胞移植 (ASCT) 结合起来.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...